Efficient small-scale conjugation of DNA to primary antibodies for multiplexed cellular targeting

Citation for published version (APA):

DOI:
10.1101/662791
10.1021/acs.bioconjchem.9b00490

Document status and date:
Published: 18/09/2019

Document Version:
Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher’s website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.tue.nl/taverne

Take down policy
If you believe that this document breaches copyright please contact us at:
openaccess@tue.nl
providing details and we will investigate your claim.

Download date: 09. Jan. 2020
Efficient Small-Scale Conjugation of DNA to Primary Antibodies for Multiplexed Cellular Targeting

Glenn A. O. Cremers,†,‡ Bas J. H. M. Rosier,†,‡ Roger Riera Brillas,†,§ Lorenzo Albertazzi,†,§ and Tom F. A. de Greef†,*

†Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Eindhoven University of Technology, P.O. Box 513, 5600 MB Eindhoven, The Netherlands
‡Computational Biology Group, Department of Biomedical Engineering, Eindhoven University of Technology, P.O. Box 513, 5600 MB Eindhoven, The Netherlands
§Molecular Biosensing for Medical Diagnostics, Department of Biomedical Engineering, Eindhoven University of Technology, P.O. Box 513, 5600 MB Eindhoven, The Netherlands

ABSTRACT: The combination of the specificity of antibodies and the programmability of DNA nanotechnology has provided the scientific community with a powerful tool to label and unambiguously distinguish a large number of subcellular targets using fluorescence-based read-out methods. Whereas primary antibodies are commercially available for a large class of targets, a general stoichiometric site-selective DNA labeling strategy for this affinity reagent is lacking. Here we present a universal, site-selective conjugation method using a small photo-cross-linkable protein G adaptor that allows labeling of antibodies of different host species with a controlled number of short oligonucleotides (ODNs). Importantly, we illustrate that this conjugation method can be directly performed on commercially available primary antibodies on a small scale and without cross-reactivity towards bovine serum albumin. In addition, we present a general benchtop-compatible strategy to purify DNA-labeled antibodies without a loss of function. The application of protein G-ODN-labeled primary antibodies is demonstrated by employing three well-known methods for detecting subcellular targets using fluorescence read-out, including flow cytometry, DNA-PAINT, and dSTORM. This work thus establishes a general and efficient platform for the synthesis of a library of unique ODN–antibody conjugates, facilitating the broader use of DNA-based programmable tags for multiplexed labeling to identify subcellular features with nanometer precision and improving our understanding of cellular structure and function.

INTRODUCTION

To unravel the structure, organization, and function of subcellular components in a crowded environment, specific orthogonal labeling of a large variety of biomolecules inside the cell is essential. Currently, antibodies are the preferred affinity reagents for the visualization of subcellular components because they offer exquisite control over specificity and are commercially available for a large class of targets. The predictability of DNA nanotechnology has provided a powerful tool for providing antibodies with unique, programmable labels that allow detection via various fluorescence-based read-out methods.1 In general, read-out methods based on DNA have the advantage that their coding capacity, in addition to a number of spectrally distinct fluorescent tags, relies on the complementarity of unique oligonucleotide (ODN) sequences, increasing the number of labels that can be simultaneously used.2,3 As a result, multiple fluorescence-based read-out methods are available that rely on the reversible binding of short imager strands,4,5 affinity-mediated signal amplification,6,7 and DNA strand displacement.8–10 In addition, advances in the field of DNA nanotechnology have provided a powerful tool for the design of well-defined nanostructures, the DNA origami technique.11–13 This development has allowed the design of nanostructures that facilitate control over optical properties (e.g., brightness, color) by the site-specific incorporation of fluorescently labeled ODNs.14,15 Combining the programmability of DNA nanotechnology with the specificity of antibody labeling therefore facilitates the design of programmable fluorescent tags that have the ability to label >100 subcellular targets and can be distinguished unambiguously.

Received: July 14, 2019
Revised: August 16, 2019
Published: August 22, 2019
Although primary antibodies are widely commercially available, a general stoichiometric site-selective ODN labeling strategy is missing. Traditionally, antibodies are functionalized with a modified ODN that targets chemical groups present in the native antibody (e.g., thiols and primary amines). However, this method lacks site-selectivity and stoichiometric control and can therefore result in antibodies with diminished binding capacity. Moreover, commercially available antibody solutions contain protein stabilizers, bovine serum albumin (BSA) in particular, which carry numerous functional groups that directly compete for reaction with the functionalized ODN. Several methods have been introduced to address these limitations, involving the introduction of noncanonical amino acids or specific labeling tags, including Snap-tags, HaloTags, and CLIP-tags. Additionally, coupling methods targeting specific regions on the antibody have been applied. However, these methods require genetic re-engineering of the antibody, are limited by the specific host species or subtype of the antibody, or are performed in the absence of stabilizing proteins.

Here we present a general, benchtop-compatible strategy to site-selectively label and purify commercially available primary antibodies with short ODNs. Importantly, we confirm that this labeling method is selective for antibodies and shows no cross-reactivity toward BSA. This selectivity is achieved using an ODN-functionalized protein G adaptor (p-G-ODN) that can be photo-cross-linked to the heavy-chain region of a native IgG antibody (Figure 1). Protein G is part of a larger class of proteins, among them protein A and protein L, which are able to selectively bind to a specific region of a native IgG antibody and therefore allow site-selective functionalization of antibodies. In this study, we optimized the ODN coupling efficiency to protein G, which allowed the direct conjugation of unpurified p-G-ODN constructs to a native antibody, making multiplexed antibody labeling efficient and less time-consuming. We show that this strategy is compatible with human IgG1, mouse IgG2a, and rabbit IgG antibodies, which together cover >80% of the commercially available primary antibodies. In combination with a universal, benchtop-compatible purification method, we report on the successful labeling and purification of a subset of primary antibodies. To illustrate the universal applicability of the coupling strategy, cellular labeling with p-G-ODN–antibody constructs is evaluated using flow cytometry and super-resolution microscopy techniques, including stochastic optical reconstruction microscopy (STORM) and DNA point accumulation for imaging in nanoscale topography (DNA-PAIN). Our results show successful cellular labeling using the p-G-ODN–antibody conjugates and underline that covalent coupling of the p-G-ODN construct to the antibody is required when multiplexed cellular labeling is performed.

**RESULTS AND DISCUSSION**

To facilitate the efficient synthesis of multiple unique p-G-ODN constructs, we first focused on a labeling method to couple maleimide-functionalized ODNs to protein G with a high yield. Previous work showed that the N-terminal cysteine formed an unreactive thiazolidine adduct during pG expression, which limited the pG-ODN conjugation efficiency to ~15%. In this previous work, it was hypothesized that the introduction of an additional amino acid before the N-terminal cysteine would resolve this problem and increase the conjugation efficiency. To this end, we site-specifically inserted a serine N-terminal to the cysteine and found that after pG expression, no adduct formation was observed (Figure S1).

As a result, the pG-ODN coupling efficiency was increased to >90% when pG was incubated with a five-fold molar excess of maleimide-functionalized ODN (Figure S2). Subsequently, we investigated if the pG-ODN reaction mixture could directly be used for antibody coupling without the initial purification of the pG-ODN construct. To this end, we incubated Cetuximab, a monoclonal IgG1 antibody, with different molar equivalents of pG-ODN. We compared the formation of pG-ODN–
antibody conjugates using the unpurified pG-ODN reaction mixture and purified pG-ODN. SDS-PAGE analysis was used to monitor product formation, and gel band intensity analysis showed that >80% of the heavy chains were successfully labeled with pG-ODN using a 10-fold molar excess of unpurified pG-ODN (Figure 2A and Figure S3). In comparison, we observed >90% labeling efficiency when purified pG-ODN was used (Figure S4). Additionally, the lyophilization of the pG-ODN constructs did not decrease the reported conjugation efficiency, making these constructs ideal for long-term storage and shipping (Figure S5). We note that the antibody conjugation efficiency (~80%) does not match the coupling efficiency observed after pG-ODN coupling (>90%); however, we hypothesize that pG—antibody binding is preferred over pG-ODN—antibody coupling due to the steric hindrance and electrostatic repulsion induced by the ODN. Nevertheless, on the basis of the observed heavy-chain labeling efficiency for unpurified pG-ODN, we expect that >95% of all antibodies (two heavy chains) contain at least one ODN sequence.

To examine the general applicability of the pG-ODN labeling strategy, we evaluated the coupling efficiency for antibodies of different host species. Previously, it was shown that pG was also able to photo-cross-link to mouse IgG2a and Rabbit IgG.27 Rabbit IgGs, in particular, are an important class of antibodies because rabbits are the host species in which most primary antibodies are raised.28 Incubating both mouse IgG2a (mIgG2a) and rabbit IgG with a 10-fold excess of pG-ODN showed successful antibody coupling, emphasizing the universal applicability of pG-ODN labeling (Figure 2B).

Because commercially available primary antibodies are typically supplemented with protein stabilizers (e.g., BSA, glycerol, sodium azide), pG-ODN antibody labeling should be compatible with the presence of these additives. BSA, in particular, is known to interfere with more classic ODN-labeling methods targeting functional groups in the antibody (e.g., lysine, cysteine). Commercially available kits can be used to remove BSA; however, these protocols rely on extensive washing steps, resulting in the extensive loss of antibody. The exclusive selectivity of pG-ODN towards the heavy-chain region should overcome this problem, making the need for BSA-free antibody solutions redundant. To test this, we performed the coupling of an antibody to pG-ODN in the presence of 0.07% (w/v) BSA. As expected, the labeling of Cetuximab in the presence of BSA did not result in cross-reactivity, confirming the selectivity of pG-ODN constructs (Figure 2C). Additionally, we evaluated the coupling efficiency of pG-ODN in the presence of other common antibody additives, including TWEEN-20, glycerol, and sodium azide. Sodium azide is known to quench the reactive triplet state of p-Bpa and is therefore likely to inhibit the pG-ODN cross-linking.29 Whereas TWEEN-20 did not alter the coupling efficiency, both glycerol and sodium azide inhibited the formation of pG-ODN—antibody constructs (Figure S6). However, buffer exchange of the antibody using ultrafiltration to a glycerol/sodium azide free buffer did restore the coupling efficiency. From this, we conclude that the pG-ODN labeling strategy can be used in combination with commercially available antibodies.

We next focused on the development of a universal purification approach to remove excess pG-ODN. To this extent, we systematically evaluated different purification methods that either focus on size-based separation or are specifically designed for antibody purification. First, we tested the separation of pG-ODN—antibody constructs and pG-ODN using size-exclusion chromatography (SEC). The relatively large difference in molecular weight between pG-ODN and labeled antibodies, 15 and 180 kDa, respectively, should provide enough separation to effectively purify the pG-ODN—antibody. To this end, we applied a high-performance liquid chromatography (HPLC) system with a size exclusion column that has a fractionation range between 5 × 10^3 and 1.25 × 10^6
Da. Using this approach, the pG-ODN–antibody conjugate was well-separated from unreacted pG-ODN (Figure S7). However, despite the excellent separation, we note that HPLC requires specialized equipment. Moreover, HPLC purification results in high sample dilution, making this method less appropriate for small sample volumes, which is typically the case when primary, more expensive antibodies are labeled. To address this limitation, we evaluated a second size-based purification technique using ultrafiltration. We performed a repetitive dilution concentration process using a regenerated cellulose membrane with a 100 kDa molecular weight cutoff (MWCO). In this process, the large pG-ODN–antibody should be retained by the membrane, whereas the smaller pG-ODN should flow through. In contrast with SEC, ultrafiltration resulted in limited separation of the pG-ODN–antibody and pG-ODN with a recovery yield of 25% and contamination of 19% (Figure 2D, bottom). The recovery yield and contamination percentage were calculated by gel analysis of the purified product and known concentrations of a reference antibody (Figure S8). To improve the separation of the pG-ODN–antibody and the free pG-ODN, we evaluated the performance of multiple (denaturing) washing buffers. Whereas the use of different washing buffers did improve the recovery yield (68%), the separation remained limited (Figure S9). Further optimization of this purification process, for example, the use of an acidic washing buffer, could therefore be performed to improve the limited separation. 29–31

To design a universal benchtop-compatible purification method, we therefore decided to turn our attention to antibody-specific purification methods. In addition to protein G, several recombinant proteins are available that target specific regions of an antibody, including proteins A and L. Whereas protein A overlaps with the binding site of protein G, protein L specifically binds to kappa light chains of mouse and human IgG monoclonal antibodies. 32 Using commercially available magnetic beads functionalized with protein L, we were able to successfully purify pG-ODN-functionalized Cetuximab (hlG1) from pG-ODN (Figure S10). However, the limited compatibility of protein L with different subclasses or host species of antibodies prevents the general application of this purification method. Therefore, we developed a purification method that utilizes the protein L magnetic beads to target free pG-ODN, instead of the labeled antibody. We achieved this via the covalent attachment of a scavenging antibody, typically a secondary, less expensive antibody, to protein L beads by cross-linking the primary amines of both proteins using a bis-succinimide ester-activated PEG compound BS(PEG) 5 (Figure 2D, top). Protein L ensures the correct orientation of the scavenger antibody, making the Fc region available for free pG-ODN binding. We evaluated multiple cross-linking conditions to increase the binding capacity of the scavenger beads and showed the successful capture of pG-ODN (Figure S11). Subsequently, we confirmed that this method can be used to purify pG-ODN-labeled antibodies, and after desalting of the purified mixture, a recovery of 58% and contamination of only 3% were achieved (Figure 2D, bottom; Figure S12). Whereas the relatively low recovery yield could be improved by further optimization of the washing steps, we primarily focused on the low contamination. Additionally, we note that the recovery yield is decreased to 30% when antibodies that have a high intrinsic affinity for protein L (hlG, mlG) are purified (Figure S13). Lastly, it was shown that this scavenging approach could be performed on a small scale (5 μg) and was compatible with Fc-fusion proteins (Figure S14). Protein-L-functionalized magnetic beads, in combination with a scavenging antibody, therefore provide an additional platform for the small-scale purification of antibodies from different host species and subtypes.

To test the activity of the pG-ODN functionalized antibodies after labeling and purification, we used fluorescence-activated cell sorting (FACS) analysis. To this end, we functionalized Cetuximab with a pG-ODN docking strand a. Subsequently, we preincubated pG-ODN-labeled Cetuximab that was purified using SEC, ultrafiltration, or magnetic scavenging beads with a CY5-functionalized ODN, a′, complementary to the pG-ODN docking strand. Eventually, we incubated A431 carcinoma cells, expressing high levels of epidermal growth factor receptor (EGFR), with pG-ODN–Cetuximab, hybridized to a CY5-labeled ODN, and subjected them to flow cytometry. In all cases, an increase in the fluorescence intensity was observed, indicating the binding of pG-ODN–Cetuximab to the EGFR receptor (Figure 3A and Figure S15). To emphasize the importance of irreversible coupling, we compared the labeling efficiency and cross-contamination of antibodies labeled covalently (+hv) and noncovalently (−hv) with pG-ODN. To this end, Cetuximab was incubated with pG-ODN in the presence and absence of UV illumination. Subsequently, A431 cells were incubated with pG-ODN–

---

**Figure 3.** Flow cytometric analysis of EGFR-expressing A431 cells using 10 nM pG-ODN-functionalized Cetuximab, a, hybridized to a CY5-functionalized ODN, a′. (A) Antibody activity after purification using SEC, ultrafiltration, and magnetic beads. The fluorescence intensity of pG-ODN-Cetuximab-labeled A431 cells was compared with that of A431 cells incubated with only pG-ODN. (B) Labeling efficiency and (C) cross-contamination of pG-ODN noncovalently (−hv) or covalently (+hv) coupled to Cetuximab. pG-ODN-functionalized Cetuximab was incubated for 1 h with a 20 mol equiv of a competing pG-ODN sequence. MFI represents the median fluorescence intensity, and error bars represent the SD (n = 3).
Cetuximab to label the EGFR receptor. After labeling, a CY5-functionalized ODN, complementary to the pG-ODN sequence, was introduced, and the cells were analyzed using flow cytometry. The 2.2-fold difference in median fluorescence shows a clear increase in labeling efficiency when the antibody is labeled covalently (Figure 3B), which underlines the importance of irreversible labeling.

Because cellular labeling procedures are typically performed with multiple antibodies, traces of pG-ODN present after purification could bind other antibodies, resulting in unwanted cross-contamination. To evaluate the degree of cross-contamination, we incubated noncovalently and covalently labeled pG-ODN--Cetuximab with a 20-fold molar excess of a competing pG-ODN docking sequence, $b$, for 1 h. Subsequently, A431 cells were incubated with the reaction mixture, and after labeling of the EGFR receptor, a CY5-functionalized ODN, $b'$, complementary to the competing pG-ODN sequence, was added. The observed median fluorescence for the cells that were labeled with noncovalent pG-ODN--Cetuximab showed pG-ODN exchange resulting in cross-contamination (Figure 3C). In contrast, when pG-ODN was coupled covalently to Cetuximab via photoinduced coupling, no cross-contamination was observed. Additionally, it was shown that free Fc binding sites could be blocked during cellular labeling using a five-fold molar excess of pG compared to the competing pG-ODN sequence, nullifying cross-contamination (Figure S16). These results show that multiple pG-ODN-functionalized antibodies can be used simultaneously, even when the pG-ODN antibody coupling is not quantitative and free Fc sites are still available.

Thus far, we have shown the synthesis and purification of pG-ODN--antibody constructs and successfully used them for cellular labeling. Next, we tested the multiplex applicability of the pG-ODN labeling strategy by coupling three primary antibodies, Cetuximab, mouse IgG2a anti-CD45, and mouse IgG2a anti-CD31, to a unique pG-ODN docking sequence, $a$, $b$, and $c$, respectively. Subsequently, we performed the simultaneous labeling of three cell types with all of the pG-ODN functionalized antibodies, including A431 carcinoma cells, Jurkat T cells, and human umbilical vein endothelial cells (HUVECs) expressing EGF, CD45, and CD31, respectively. Because quantitative pG-ODN labeling was not observed for all antibodies, we introduced a five-fold molar excess of pG with respect to pG-ODN to block any remaining free Fc sites. After cellular labeling, we introduced CY5-functionalized ODNs, $a'$, $b'$, and $c'$, respectively, complementary to a specific pG-ODN docking sequence, and analyzed the cells using flow cytometry (Figure 4A). The presence of only one distinct fluorescent population per CY5-functionalized strand showed the successful labeling of targets without the exchange of pG-ODN sequences, verifying that pG-ODN--antibody conjugates are suitable for multiplexed cellular labeling and imaging (Figure 4B).

Although flow cytometry is an excellent tool to study cell populations, it is unable to provide a detailed view of the structure and organization of subcellular components. Super-resolution techniques, however, are able to visualize cellular targets with nanometer precision and therefore have the potential to increase our understanding of cell structure and function. DNA-PAINT and, in particular, exchange-PAINT, rely on the use of antibodies functionalized with a unique ODN to achieve multiplexed super-resolution imaging with a spatial resolution down to $\sim$5 nm. To illustrate that pG-ODN-functionalized primary antibodies could be directly used for DNA-PAINT, we demonstrated in situ imaging in a fixed A431 carcinoma cell using pG-ODN-functionalized Cetuximab that was purified using SEC (Figure 5A). We obtained super-resolution images of the EGFR receptor and observed little nonspecific binding when a noncomplementary imager strand was used (Figure 5B and Figure S17). Recently, Jungmann and coworkers also successfully obtained super-resolution images when using ODN-functionalized protein A and G variants as secondary, noncovalent labeling reagents for DNA-PAINT. Because pG-ODN is covalently coupled to the antibody using UV light, we additionally investigated whether the pG-ODN antibody coupling is reversed when the construct is exposed to high laser intensity, as those employed during DNA-PAINT. To validate the stability of the pG-ODN--antibody construct, we quantified the number of localizations during image acquisition over the course of 8 min (Figure 5C). The observed number of localizations remained constant over time, confirming that the photoconjugated pG-ODN--antibody construct is stable when exposed to high laser intensity. This result also allowed the use of pG-ODN--antibody constructs for cellular staining in combination with direct STORM (dSTORM), which requires high illumination power. Successful dSTORM images of the EGF receptor on A431 cells were acquired using a complementary CY5-functionalized imager strand, hybridized to a pG-ODN--Cetuximab construct (Figure 5D and Figure S18). Taken together, these results show the compatibility of the pG-ODN labeling approach with super-resolution techniques, including DNA-PAINT and dSTORM.
CONCLUSIONS

In this work, we have developed a generally applicable ODN–antibody coupling method using a small protein G adaptor that site-selectively targets the heavy chain of an IgG antibody. We successfully demonstrated pG-ODN labeling of antibodies from different host species without cross-reactivity towards BSA. Importantly, we showed that the pG-ODN labeling did not affect the native function of the antibody. In combination with the universal, benchtop-compatible purification strategy using magnetic beads, this ODN labeling method is directly applicable to commercially available primary antibodies. Because multiple pG-ODN conjugates can be constructed in parallel and lyophilized without a loss of function, the potential of the pG-ODN labeling strategy lies in the synthesis of a library of pG-ODN constructs that can directly be used for antibody labeling. This could eventually facilitate the implementation of the multiplexing abilities of DNA-based read-out methods for the detection of a large variety of subcellular components and make these methods accessible for a broader scientific community. Additionally, we envision the use of pG-ODN–antibody constructs in more quantitative imaging applications, owing to the unique ability of pG-ODN conjugates to selectively label an antibody with a controlled number of ODNs.

MATERIALS AND METHODS

Recombinant Protein Cloning, Expression, and Purification. A pET28a(+) vector encoding the pG gene as reported previously was site-specifically mutated by the insertion of an N-terminal serine using the QuikChange Lightning multi site-directed mutagenesis kit (Agilent) according to the manufacturer’s instructions using the following forward and reverse primers (ser codon underlined), 5′-TTTAAGAAGGAGATATAACATGAGTTGCTGGTCC-CATCCG-3′ and 5′-CGGATGGGACCAGCAACTCATGT-TATATCTCCTTCTAAAG-3′, respectively. Insertion was confirmed by a DNA sequencing service provided by StarSEQ (Mainz, Germany). Plasmid DNA of the pG gene was cotransformed with the pEVOL-pBpF vector, encoding for the orthogonal aminoacyl tRNA synthetase/tRNA pair (kindly provided by Peter Schultz), into E. coli BL21(DE3) (Novagen) for protein expression. A single colony of freshly transformed cells was cultured at 37 °C in 500 mL of 2xYT medium supplemented with 50 μg/mL kanamycin (Merck) and 25 μg/

Figure 5. Protein G-ODN–antibody conjugates for applications in super-resolution microscopy. (A) A431 carcinoma cells are labeled with a pG-ODN–Cetuximab construct containing either a short (11 nt) or a long (20 nt) docking strand. Subsequently, the labeled cells are fixated to a glass slide, and super-resolution images are obtained using the transient binding of a short imager strand (DNA-PAINT) or using a long irreversible binder in combination with a photoswitchable dye (dSTORM). (B) DNA-PAINT super-resolution image obtained using ATTO647N-functionalized imager strands (20 000 frames, 20 Hz frame rate). A zoom-in on two defined areas shows the distribution of EGFR receptors. (C) Number of localizations observed over the course of 8 min during a DNA-PAINT acquisition using complementary (c) or non-complementary (n.c.) imager strands. (D) Super-resolution image obtained with dSTORM using a CY5-functionalized imager strand (20 000 frames, 65.5 Hz frame rate), including a zoom-in on two defined areas that show the distribution of EGFR receptors. Scale bars: 5 and 1 μm for the zoom-in images.
mL chloramphenicol (Sigma-Aldrich). When the OD₆₀₀ of the culture reached ~0.6, protein expression was induced by the addition of β-d-1-thiogalactopyranoside (IPTG, Applichem), arabinose (Sigma-Aldrich), and the unnatural amino acid p-BpA (Bachem) in a final concentration of 1 mM, 0.02% (v/v), and 1 mM, respectively. The induced protein expression was carried out for ~18 h at 25 °C, and subsequently, the cells were harvested by centrifugation at 10 000 g for 10 min at 4 °C. The cell pellet was resuspended in BugBuster (5 mL/g pellet, Merck) supplemented with benzamide (5 μL/g pellet, Merck) and incubated for 45 min on a shaking table. The suspension supernatant was subjected to Ni-NTA resin supplemented with EDTA, and 2 mM TCEP at pH 8.0. The concentration of pG was measured on a spectrophotometer at 280 nm and SDS-PAGE under nonreducing conditions. pG-ODN conjugates were aliquoted and stored at ~80 °C.

**General Procedure for pG-ODN Antibody Labeling.** Before the conjugation of the antibody to the pG-ODN, all antibodies were buffer-exchanged to 1× PBS (pH 7.4) using Amicon 10 kDa MWCO centrifugal filters (Merck Millipore). In the absence of BSA: In a typical reaction for SDS-PAGE gel analysis, a 10 μL aliquot containing 0.4 μM of antibody and 4 μM of pG-ODN was exposed for 1 h to UV light (λ = 365 nm) at 4 °C.

In the presence of BSA: For the conjugation of the antibody to pG-ODN in the presence of BSA, the pG-ODN reaction mixture was first incubated with 15 nmol of DTT and shaken at 850 rpm for 30 min at 20 °C to deactivate remaining maleimide–ODNs. Subsequently, pG-ODN was buffer-exchanged using a Zeba spin desalting column, 7000 MWCO, 0.5 mL (Thermo Scientific).

**General Procedure for the Antibody Functionalization of Protein L Magnetic Beads.** The scavenging antibody Cetuximab (Erbitux, Merck) was buffer-exchanged to conjugation buffer (100 mM sodium phosphate, 70 mM NaCl, 0.05% Tween-20 (v/v), pH 8.0) using a Zeba spin desalting column (7000 MWCO, 0.5 mL, Thermo Scientific) according to the manufacturer's instructions.

**General Procedure for the Purification of pG-ODN Functionalized Antibody.** This procedure is optimized to purify 12.5 μL of 4 μM antibody–pG-ODN from 40 μL uncoupled pG-ODN using 25 μL of magnetic scavenging beads. Twenty-five μL of scavenging beads was washed two times in binding buffer (1× PBS, 870 mM NaCl, 0.05% Tween-20 (v/v), pH 7.4). The beads were resuspended in 37.5 μL of binding buffer, and 12.5 μL of the antibody–pG-ODN reaction mixture was added and incubated for 15 min in a rotating wheel at room temperature. The scavenging beads were washed twice with 200 μL of storage buffer (1× PBS, 0.05% Tween-20 (v/v), pH 7.4), and stored at 4 °C.

**General Procedure for the Conjugation of the ODN to pG.** For the conjugation of pG to a SMCC-functionalized ODN, an aliquot of pG was buffer-exchanged to 100 mM sodium phosphate, 25 μM TCEP, pH 7) using a PD10 desalting column (GE Healthcare). Subsequently, desalted pG was concentrated to a final concentration of 50 μM using Amicon 3 kDa MWCO centrifugal filters (Merck Millipore). Ten nmol lyophilized SMCC-functionalized ODN was reconstituted in 40 μL of 50 μM pG (2 nmol), resulting in a five times excess of maleimide–ODN. The reaction was shaken at 850 rpm for 3 h at 20 °C. The coupling efficiency was assessed using SDS-PAGE under nonreducing conditions. The purification, if applicable, of pG-ODN was performed using fast protein liquid chromatography (FPLC, AKTA Prime, GE Healthcare) with an anion-exchange HiTrap Q HP column (1 mL, GE Healthcare) using a salt gradient with a start and end concentration of 100 and 500 mM NaCl in 50 mM Tris-HCl (pH 7.5), respectively. Elution fractions were collected and analyzed by measuring online absorption at 280 nm and SDS-PAGE under nonreducing conditions. pG-ODN conjugates were aliquoted and stored at ~80 °C.
band intensity analysis using SDS-PAGE under reducing conditions.

**Cellular Labeling for Flow Cytometry.** A431, Jurkat T, and HUVECs were cultured in a 175 cm² flask. Cells were harvested at a confluency of ~80%, washed in labeling buffer (1× PBS, 0.1% BSA (w/v), pH 7.4), and diluted to a final concentration of 3.5 × 10⁶ cells/mL in labeling buffer. Subsequently, 12.5 μL of the cell suspension was incubated in a final volume of 250 μL of labeling buffer containing 10 nM of pG-ODN-labeled antibody. The reaction mixture was shaken at 400 rpm for 30 min at room temperature. Subsequently, the labeled cells were centrifuged for 5 min at 1500g, and the supernatant was removed. The pelleted cells were redissolved in labeling buffer containing 100 nM of the complementary CYS-labeled ODN. The reaction mixture was incubated and centrifuged as previously described and subsequently analyzed using flow cytometry. For the multiplexed experiment (Figure 4), the labeling buffer was supplemented with 1.5 μM pG.

**Super-Resolution Sample Preparation and Imaging.** A431 cells (ATCCCRCL-1555) were seeded on an eight-well glass-bottomed μ-slide (ibidi, Germany) overnight. Live-cell immunolabeling started with 5 min of acclimation of the cells at room temperature, followed by 5 min of acclimation at 4 °C. Cells were incubated for 45 min at 4 °C in DMEM/3% BSA with 1 μg/mL of pG-ODN–Cetuximab. Then, three 5 min washes with PBS at 4 °C were followed by formalin 5% and glutaraldehyde 0.25% fixation for 10 min. Ultimately, cells were washed three times for 5 min with PBS and stored in the fridge before imaging. Super-resolution images were acquired using a Nikon N-STORM microscope in total internal reflection fluorescence (TIRF) mode. The system was equipped with a Nikon 100X, 1.49 NA oil immersion objective and an Andor iXON3 camera. Images were acquired onto a 256 × 256 × 40.96 μm of the cell suspension was incubated for 10 min. Ultimately, cells were incubated and centrifuged as previously described and subsequently analyzed using flow cytometry. For the multiplexed experiment (Figure 4), the labeling buffer was supplemented with 1.5 μM pG.

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.bioconjchem.9b00490.

Extensive experimental methods and supplemental figures of purification strategies and characterization experiments (PDF)

### Author Information

**Corresponding Author**
*E-mail: t.f.a.d.greef@tue.nl.*

**ORCID**

Tom F. A. de Greef: 0000-0002-9338-284X

**Author Contributions**

1G.A.O.C. and B.J.H.M.R. contributed equally to this work.

### Notes

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

We thank L. A. Tiemeijer and C. M. Sahlgren for providing and culturing the HUVECs. Sinem K. Saka from the Wyss Institute for Biologically Inspired Engineering is gratefully acknowledged for valuable insights and fruitful discussions. This work was supported by the European Research Council (ERC) (project no. 677313 BioCircuit), an NWO-VIDI grant from The Netherlands Organization for Scientific Research (NWO, 723.016.003), and funding from the Ministry of Education, Culture and Science (Gravity programs, 024.001.035 & 024.003.013)

### REFERENCES


with Digitally Tunable Optical Properties Self-Assembled from DNA.
Sci. Adv. 3 (6), e1602128.


(33) Results for “Primary Antibodies” 1 abcam: Antibodies, Proteins, Kits. https://www.abcam.com/products?sortOptions=

DOI: 10.1021/acs.bioconjchem.9b00490
Bioconjugate Chem. 2019, 30, 2384–2392